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Abstract
Many members of The Japanese Environmental Mutagen Society (JEMS) have significantly contributed to guidelines
on chemical genotoxicity. The guidelines have been useful for the hazard identification and risk assessment of
genotoxic chemicals. However, risk assessors and developers of drugs and other commercial products might
eliminate beneficial chemicals from further development simply based on positive results of genotoxicity testing.
Experts in the field of genotoxicity should better characterize the biological significance of genotoxicants and more
correctly assess human risk. I hope that one of the next challenges undertaken by JEMS will be to assess the
human risk of genotoxic chemicals more correctly based on the precise analysis of their mechanisms of action.
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The Japanese Environmental Mutagen Society (JEMS) was
established in 1972; its main purpose is to investigate
environmental mutagens that may affect public health.
Therefore, one of the concerns of JEMS is to characterize
the genotoxicity, including mutagenicity, of chemicals to
which humans are exposed. A large number of relatively
simple in vitro and in vivo test methods have been devel-
oped to detect genotoxic compounds and several of these
are internationally standardized as test guidelines by the
Organisation for Economic Co-operation and Develop-
ment (OECD) [1–13]. In addition, strategic guidelines (or
international consensus papers) have been published to
describe how chemical genotoxicity should be evaluated
and regulated to reduce the risk for humans. One example
is the S2 guidelines of the International Conference on
Harmonization of Technical Requirement for Registration
of Pharmaceuticals for Human Use (i.e., ICH-S2 guide-
lines) [14–16]. Many members of JEMS have significantly
contributed to such guidelines, and currently most new
chemicals are evaluated using such test methods because
of more strict regulation of genotoxicants than before.
These guidelines have been very useful for the hazard
identification and risk assessment of genotoxic chemicals.
However, risk assessors and developers of drugs and other
commercial products might eliminate chemicals from
further development simply based on positive results of
genotoxicity testing. For example, the bacterial reverse
mutation test (i.e., the Ames test) is generally used in
the early screening of pharmaceutical candidates, and
many drug developers believe that positive results in
this assay necessitate the withdrawal of the candidate
from further development. Although experts in the field of
genotoxicity know that Ames-positive results do not always
mean a risk to humans, discarding positive candidates is
thought to be cost-effectiveness, i.e., extensive efforts would
be required to demonstrate that the Ames-positive results
were not relevant to human. This strategy is also preferable
from the viewpoint of pharmaceutical regulation. However,
might not this strategy also reduce the likelihood of
developing useful pharmaceuticals? Experienced medi-
cinal chemists avoid synthesizing pharmaceuticals that
have known genotoxic substituents and/or possibly geno-
toxic structure, thus narrowing the chemical-space of new
pharmaceutical candidates. Historically, some genotoxic
pharmaceuticals have been accepted for medical use by
regulatory agencies based on a risk-benefit consideration
but the indications are largely limited to the treatment of
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cancers or infectious diseases. Since there are many other
life-threating and/or intractable diseases, the elimination
of genotoxicity from chemical-space might be a disadvan-
tage for patients with serious diseases. I believe that this is
a very important issue, which genotoxicity experts should
carefully consider.
How can experts better characterize the biological
significance of genotoxicants and more correctly assess
human risk? A general approach for examining chemicals
is to use a battery of genotoxicity tests that can detect dif-
ferent kinds of genotoxicity, i.e., use a weight of evidence
(WoE) approach. For example, the ICH-S2(R1) guideline
[16] requires two types of in vivo genotoxicity tests when
a chemical shows a positive result in an in vitro genotoxi-
city test using mammalian cells. However, two negative in
vivo test results might be insufficient in terms of conclud-
ing that a chemical poses absolutely no genotoxicity risk
to humans. This is true because in vivo genotoxicity test
methods are generally insensitive compared to in vitro
ones. Negative results in rodent carcinogenicity bioassays
with rats and mice would substantially support a conclu-
sion that the genotoxic active response was not relevant,
but the testing of all genotoxic agents for cancer induction
in rodents is just not feasible. So, how might experts ap-
proach this issue? The first issue of “Genes and Environ-
ment”, published ten years ago, included my report, in
which suggesting that one approach to understanding the
role of genotoxicity in carcinogenesis would be the precise
analysis of the genotoxic mechanisms of action (MoA)
[17]. And here, I reiterate the same suggestion to resolve
the issue mentioned above by introducing two approaches
for analyzing the MoA and for assessing human risk based
on the MoA.
One of the approaches is based on the availability of
new technologies. My colleagues and I have integrated
the DNA adductome approach, i.e., identification of the
types and frequency of chemically-induced DNA adducts
[18] to assess the DNA-damaging capability of in vitro
micronucleus (MN) test-positive chemicals. In addition
to the Ames test, the in vitro MN test is generally used for
the screening of chemicals for genotoxicity, but it often
produces false-positive results [19]. When a positive MN
result is obtained for a chemical, the first consideration in
terms of human risk is whether the chemical reacted with
DNA directly or indirectly; the former would indicate
human risk while the latter would potentially indicate
the existence of a no-adverse-effect level. Thus, DNA
adductome analysis is a useful method for determining
MoA. In the experiments using 9 chemicals positive in
the in vitro MN test with Chinese hamster lung cells, 6
carcinogens formed DNA-adducts while 3 non-carcinogens
did not [20]. These findings indicate that DNA adductome
analysis can provide useful information about the potential
of a positive in vitro result to pose a human risk.
Another approach is case-by-case that considers the
chemical and/or biological (pharmacological in pharma-
ceuticals) properties of a chemical in a WoE approach.
As a case study, MP-124, a novel poly(ADP-ribose)poly-
merase-1 (PARP-1) inhibitor, is being developed as a
neuroprotective agent against acute ischemic stroke
[21, 22], and my colleagues and I hypothesized during
the early phase of development that the pharmacological
property might produce a genotoxic event because PARP-1
is a key enzyme involved in the repair of DNA damage
[23–27]. Therefore, the genotoxicity of MP-124 was care-
fully investigated by using the WoE approach [28]. The
compound was positive in the in vivo immature erythrocyte
MN test using male rats treated by intravenous infusion
[28], and the MoA of the positive finding was investigated.
Since MP-124 inhibits PARP-1 competitively and the en-
dogenous competitor is nicotinamide adenine dinucleotide
(NAD) [21, 22], Yamamura et al. examined whether or not
co-treatment with nicotinic acid, the precursor of NAD, to
rats could inhibit the induction of MN by MP-124; co-
treatment clearly inhibited MN induction [28]. They also
examined if co-treatment of cyclophosphamide and nimus-
tine, both reference genotoxicity positive-controls, with
NAD under the same experimental conditions altered their
ability to induce MN, but no inhibition was observed [28].
These results indicate that the ability of MP-124 that in-
duced MN in vivo is related to its pharmacological proper-
ties and therefore, this mechanism is expected to result in a
threshold for MN induction. This understanding allows for
the establishment of a safe margin of exposure for the
therapeutic use of MP-124. Although this is a case study, a
similar approach can be applied to other cases if genotoxi-
city experts well understand the chemical/biological prop-
erties of the chemical of interest in advance, and hopefully
before starting the development of new pharmaceuticals.
As members of JEMS, we know that there are still
many issues that should be investigated like the above
examples, but it seems that the present genotoxicity test
guidelines are considered by those who are not experts
on genotoxicity to be sufficient for assessing the geno-
toxic risk of chemicals. To bridge any discordance in un-
derstanding between us and the rest of the scientific and
regulatory community, I think that we should more ac-
tively inform the non-experts of our update that is more
logical for their satisfaction beyond the simple testing re-
sults on chemical genotoxicity. Therefore, I hope that
one of the next challenges undertaken by JEMS will be
to assess the human risk of genotoxic chemicals more
correctly based on the precise analysis of their MoA.
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